NATICK, Mass. , Aug. 27, 2024 /PRNewswire/ -- Pillar Biosciences, Inc .
, the leader in Decision MedicineTM, has announced the global launch of oncoRevealTM Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy. A team at New York's Memorial Sloan Kettering Cancer Center (MSK), will be the first to utilize oncoReveal TM Nexus, which will be branded MSK-REACT. MSK has already received NYS DOH approval for clinical implementation of MSK-REACT, enabling a more streamlined NGS workflow to help patients get on the right therapy sooner.
oncoReveal TM Nexus assesses key driver genes for both hematological and solid tumor malignancies in one multiplex reaction. The assay has a fully automatable workflow that can be performed by any clinical laboratory, batching up to eighty-one patient samples in a single Illumina MiSeqTM sequencing run, using as little as 2.5 ng DNA per patient sample.
With a sample-to-report time within 2-3 days after DNA isolation, a laboratory deploying this panel will be able to quickly assess key driver alterations prior to initiating the laboratory process for comprehensive genomic profiling (CGP), enabling more rapid time-to-treatment and laboratory cost savings. "For the last few years, industry dialogue surrounding NGS testing has been about whether to use small panel targeted sequencing .